Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001628280-25-011736
Filing Date
2025-03-10
Accepted
2025-03-10 17:01:01
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A a2024proxy-defa14a.htm DEFA14A 33167
2 GRAPHIC cumberlandlogoa02a01a.jpg GRAPHIC 12534
3 GRAPHIC xa01a.jpg GRAPHIC 2405
  Complete submission text file 0001628280-25-011736.txt   55053
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33637 | Film No.: 25724640
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)